Double-blind randomized phase II results comparing concurrent high-dose cisplatin chemorradiation (CRT) plus debio 1143 or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN): A GORTEC study

被引：0
|
作者：
Bourhis, J. [1 ]
Sun, X. [2 ]
Pointreau, Y. [3 ]
Sire, C. [4 ]
Le Tourneau, C. [5 ]
Coutte, A. [6 ]
Kaminsky-Forrett, M-C. [7 ]
Alfonsi, M. [8 ]
Boisselier, P. [9 ]
Martin, L. [10 ]
Delord, J-P. [11 ]
Clatot, F. [12 ]
Miroir, J. [13 ]
Rolland, F. [14 ]
Crompton, P. [15 ]
Brienza, S. [15 ]
Szyldergemajn, S. A. [15 ]
Even, C. [16 ]
Tao, Y. [17 ]
机构：
[1] CHU Vaudois, Radiat Oncol, Lausanne, Switzerland
[2] HNFC, Radiat Oncol, Belfort, France
[3] Ctr Jean Bernard, Radiat Oncol, Le Mans, France
[4] Hop Scorff, Ctr Hosp Bretagne Sud, Radiat Oncol, Lorient, France
[5] Inst Curie, Med Oncol, Paris, France
[6] CHU Amiens Picardie Site Nord, Oncol Radiotherapy, Amiens, France
[7] Inst Cancerol Lorraine Alexis Vautrin, Radiat Oncol, Vandoeuvre Les Nancy, France
[8] Inst Ste Catherine, Radiat Oncol, Avignon, France
[9] ICM Reg Canc Inst Montpellier, Radiat Oncol, Montpellier, France
[10] Ctr Radiotherapie Gillaume Le Conquerant, Radiat Oncol, Le Havre, France
[11] Inst Univ Canc Toulouse Oncopole, Med Oncol, Toulouse, France
[12] Ctr Henri Becquerel, Med Oncol, Rouen, France
[13] Ctr Jean Perrin, Radiat Oncol, Clermont Ferrand, France
[14] ICO Inst Cancerol Ouest Rene Gauducheau, Radiat Oncol, St Herblain, France
[15] Debiopharm Int SA, CR&D, Lausanne, Switzerland
[16] Inst Gustave Roussy, Med Oncol, Villejuif, France
[17] Inst Gustave Roussy, Radiat Oncol, Villejuif, France
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA65
引用
收藏
页码：902 / 902
页数：1
相关论文
共 50 条
  • [31] Primary results of the phase III JAVELIN head & neck 100 trial: Avelumab plus chemoradiotherapy (CRT) followed by avelumab maintenance vs CRT in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN)
    Cohen, E. E.
    Ferris, R. L.
    Psyrri, A.
    Haddad, R.
    Tahara, M.
    Bourhis, J.
    Harrington, K. J.
    Chang, P. M-H.
    Lin, J-C.
    Razaq, M.
    Teixeira, M. M.
    Lovey, J.
    Chamois, J.
    Rueda Dominguez, A.
    Hu, C.
    Dvorkin, M.
    De Beukelaer, S.
    Pavlov, D.
    Thurm, H.
    Lee, N.
    ANNALS OF ONCOLOGY, 2020, 31 : S658 - S658
  • [32] EFFECT OF LAPATINIB MONOTHERAPY ON APOPTOSIS AND PROLIFERATION: RESULTS OF A PHASE II RANDOMISED STUDY IN PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
    del Campo, J. M.
    Sebastian, P.
    Hitt, R.
    Carracedo, C.
    Lokanatha, D.
    Bourhis, J.
    Harrington, K.
    Midwinter, D.
    El Hariry, I.
    Biswas-Baldwin, N.
    ANNALS OF ONCOLOGY, 2008, 19 : 217 - 217
  • [33] A phase I dose-finding study of metformin in combination with concurrent cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma
    Gulati, Shuchi
    Yaniv, Benyamin
    Palackdharry, Sarah
    Takiar, Vinita
    Mierzwa, Michelle Lynn
    Riaz, Muhammad Kashif
    Morris, John Charles
    Xie, Changchun
    Gutkind, J. Silvio
    Desai, Pankaj B.
    Sadraei, Nooshin Hashemi
    Wise-Draper, Trisha Michel
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [34] The IAP antagonist xevinapant, in combination with high-dose cisplatin chemoradiotherapy, induces NF-kB and apoptotic pathway biomarkers in patients with high-risk locally advanced squamous cell carcinoma of the head and neck
    Piggott, Luke
    Gavillet, Bruno
    Brichory, Franck
    Gollmer, Kathrin
    Bouisset, Florilene
    Vuagniaux, Gregoire
    CANCER RESEARCH, 2022, 82 (12)
  • [35] A phase II study of nimotuzumab (TheraCim-hR3) concurrent with cisplatin/radiotherapy in patients with locally advanced head and neck squamous cell carcinoma
    Ang, Mei-Kim
    Montoya, Jose Enrique
    Tharavichitkul, Ekkasit
    Lim, Cindy
    Tan, Terence
    Wang, Lan Ying
    Wee, Joseph
    Soong, Yoke-Lim
    Fong, Kam-Weng
    Ng, Quan Sing
    Tan, Daniel Shao-Weng
    Toh, Chee-Keong
    Tan, Eng-Huat
    Lim, Wan-Teck
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2021, 43 (05): : 1641 - 1651
  • [36] Preliminary report of phase II study of neoadjuvant chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in locally advanced squamous cell carcinoma of the head and neck cancer (SCCHN) patients
    Chitapanarux, I.
    Lorvidhaya, V.
    Tharavichitkul, E.
    Sittitrai, R.
    Pattarasakulchai, I.
    Kamnerdsupaphon, P.
    Sukthomyal, V.
    EJC SUPPLEMENTS, 2005, 3 (02): : 311 - 312
  • [37] Results of a randomized phase III study of nimotuzumab in combination with concurrent radiotherapy and cisplatin versus radiotherapy and cisplatin alone, in locally advanced squamous cell carcinoma of the head and neck.
    Patil, Vijay Maruti
    Noronha, Vanita
    Joshi, Amit
    Agarwal, Jaiprakash
    Laskar, Sarbani Ghosh
    Budrukkar, Ashwini
    Murthy, Vedang
    Kannan, Sadhana
    Bhattacharjee, Atanu
    Chaturvedi, Pankaj
    Pai, P. S.
    Chaukar, Devendra
    D'cruz, Anil K.
    Juvekar, S.
    Manjrekar, Aparna
    Mathrudev, Vijayalakshmi
    Nawale, Kavita Prakash
    Bhelekar, Arti
    Banavali, Shripad Dinanath
    Prabhash, Kumar
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [38] Phase II Randomized Trial of Postoperative Chemoradiation Plus Cetuximab for High-risk Squamous Cell Carcinoma of the Head and Neck (RTOG 0234)
    Kies, M. S.
    Harris, J.
    Rotman, M. Z.
    Myers, J. N.
    Foote, R. L.
    Machtay, M.
    Khuntia, D.
    Straube, W. L.
    Ang, K. K.
    Harari, P. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S14 - S15
  • [39] PHASE-II STUDY OF HIGH-DOSE IFOSFAMIDE AS A SINGLE AGENT AND IN COMBINATION WITH CISPLATIN IN THE TREATMENT OF ADVANCED AND OR RECURRENT SQUAMOUS-CELL CARCINOMA OF HEAD AND NECK
    PAI, VR
    PARIKH, DM
    MAZUMDAR, AT
    RAO, RS
    ONCOLOGY, 1993, 50 (02) : 86 - 91
  • [40] Nivolumab (Nivo) and ipilimumab (Ipi) in combination with radiotherapy (RT) in high-risk patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).
    Johnson, Jennifer Maria
    Bar Ad, Voichita
    Lorber, Emily
    Poller, Dawn
    Manukian, Gregor
    Luginbuhl, Adam
    Curry, Joseph M.
    Cognetti, David M.
    Keith, Scott W.
    Axelrod, Rita Susan
    Rodeck, Ulrich
    Harshyne, Larry
    Argiris, Athanassios
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345